Tag: btk inhibitor

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026...

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -

Lilly reports second-quarter 2025 financial results and raises guidance

Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year...

Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025

LEXINGTON, Mass., July 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available,...

Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million

SHANGHAI, July 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and...

Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of...

As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52...

Everest Medicines to Host Virtual Nephrology-Focused KOL Event on June 30, 2025

SHANGHAI, June 26, 2025 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it will host a virtual nephrology-focused key opinion leader (KOL) event on Monday, June 30, 2025 at 8:00 AM ET. For English speakers, please click here to register. For individuals preferring instant Chinese translation, please click here.

IMBRUVICA® (ibrutinib) reçoit un avis favorable du CHMP pour le traitement des patients atteints d’un lymphome à cellules du manteau (LCM) non préalablement traités...

En attendant la décision finale de la Commission européenne, le régime offre une nouvelle norme de soins pour les patients éligibles atteints d’LMC^1,2

En termes d’efficacité, une comparaison indirecte des traitements suggère un avantage significatif d’IMBRUVICA® (ibrutinib) associé au vénétoclax par rapport à l’acalabrutinib associé au vénétoclax...

Les résultats d’études croisées de l’association ibrutinib et vénétoclax en première intention montrent un bénéfice clinique significatif pour une durée fixe, ainsi qu’une probabilité accrue de maladie résiduelle minimale indétectable et de survie sans progression par rapport à l’association acalabrutinib et vénétoclax¹

Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect...

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax¹

Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast Period (2025-2034) | DelveInsight

The multiple sclerosis market is growing due to rising prevalence, earlier diagnosis, and wider access to care. Demand is fueled by advancements in DMTs...

Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the...

EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsBtk inhibitor

New Anglia University: Is Spending Six Years Abroad Still the Best Route Into Medicine?

Transaction in Own Shares

A $350B opportunity: Canada’s next phase of growth to be driven by AI and digital technologies

Tag: btk inhibitor

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026...

Lilly reports second-quarter 2025 financial results and raises guidance

Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025

Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million

Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of...

Everest Medicines to Host Virtual Nephrology-Focused KOL Event on June 30, 2025

IMBRUVICA® (ibrutinib) reçoit un avis favorable du CHMP pour le traitement des patients atteints d’un lymphome à cellules du manteau (LCM) non préalablement traités...

En termes d’efficacité, une comparaison indirecte des traitements suggère un avantage significatif d’IMBRUVICA® (ibrutinib) associé au vénétoclax par rapport à l’acalabrutinib associé au vénétoclax...

Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect...

Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast Period (2025-2034) | DelveInsight

Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us